Insulin Co-op Urges FDA to Abolish Phase 3 Trials for Insulin Biosimilars

Drug Industry Daily
A A
The FDA should abandon requirements for Phase 3 clinical trials for insulin biosimilars, an emerging patient co-operative says.

To View This Article:

Login

Subscribe To Drug Industry Daily